会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • INTEGRIN CD18 IS A NOVEL STROMAL STEM CELL MARKER AND FUNCTIONS TO PROMOTE OSTEOGENESIS
    • INTEGRIN CD18是一种新的结构干细胞标记和功能来促进骨质疏松
    • WO2006029347A3
    • 2006-12-07
    • PCT/US2005032220
    • 2005-09-06
    • UNIV MARYLANDZHANG LIMIURA YASUOSHI SONGTAO
    • ZHANG LIMIURA YASUOSHI SONGTAO
    • G01N33/567A01N1/02C12N5/077C12N5/0775
    • C12N5/0663A61K35/28A61K48/00A61K2035/124G01N33/56966Y10T436/25375
    • The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the BMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18.
    • 本发明涉及用于从骨髓细胞,脂肪细胞或外周血中选择富含BMSSC的细胞群的新型骨髓基质干细胞(BMSSC)标记物CD18。 本发明还涉及使用本领域已知的技术例如荧光辅助细胞分选,免疫磁性法,流量显微荧光法,免疫荧光,免疫过氧化物酶,基于CD18在其表面上的选择性表达来选择富集BMSSC的细胞群的方法 染色,放射免疫测定和免疫亲和层析。 本发明进一步针对基于CD18表达分离的BMSSC及其用于治疗各种疾病的用途。 一方面,用具有CD18正常基因的载体转化BMSSC,并施用转化的BMSSC以治疗涉及CD18 CD18表达异常表达的骨退行性疾病和骨疾病。
    • 2. 发明申请
    • COMPOSITIONS AND METHODS UTILIZING FIBRIN BETA CHAIN FRAGMENTS OF THE BBETA CHAIN OF FIBRINOGEN
    • 利用纤维蛋白原β链纤维蛋白原链断链碎片的组合物和方法
    • WO2009038729A3
    • 2009-12-30
    • PCT/US2008010832
    • 2008-09-17
    • REGENERX BIOPHARMACEUTICALSUNIV MARYLANDMEDVED LEONIDZHANG LIYAKOVLEV SERGIYGOLDSTEIN ALLAN LCROCKFORD DAVID
    • MEDVED LEONIDZHANG LIYAKOVLEV SERGIYGOLDSTEIN ALLAN LCROCKFORD DAVID
    • A61K38/16C07K14/435
    • C07K14/75
    • A composition including a peptide sequence of the formula ßX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type ß15-42 monomer sequence per se, and wherein the peptide sequence is other than (ß15-66)2 dimer having two chains with each chain limited to wild type amino acids ß15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4. In such methods and combinations, a dimer of the peptide sequence may include amino acids 15-66 of the fibrin beta chain.
    • 一种组合物,其包含式X 1 -X 2的肽序列,所述肽序列对应于纤维蛋白原的Bβ链的纤维蛋白β链片段的氨基酸序列,其中X 1代表所述肽序列的N-末端,并且X 2 代表肽序列的C-末端,其中所述肽序列包含X1和X2之间的额外氨基酸,其中所述肽序列可含有非天然存在的氨基酸残基,其中所述肽序列不是野生型 其中所述肽序列不是具有两条链的(β15-66)2二聚体,其中每条链限于野生型氨基酸β15-65,并且每条链还包含非天然存在的Gly 每个链的位置66。 用于治疗和药物组合的方法可以包括多肽试剂,例如胸腺素β4。在这样的方法和组合中,肽序列的二聚体可以包括纤维蛋白β链的氨基酸15-66。